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OBJECTIVE—Loss of lipin 1 activity causes lipodystrophy and
insulin resistance in the ﬂd mouse, and LPIN1 expression and
common genetic variation were recently suggested to inﬂuence
adiposity and insulin sensitivity in humans. We aimed to conduct
a comprehensive association study to clarify the inﬂuence of
common LPIN1 variation on adiposity and insulin sensitivity in
U.K. populations and to examine the role of LPIN1 mutations in
insulin resistance syndromes.
RESEARCH DESIGN AND METHOD—Twenty-two single nu-
cleotide polymorphisms tagging common LPIN1 variation were
genotyped in Medical Research Council (MRC) Ely (n  1,709)
and Hertfordshire (n  2,901) population-based cohorts. LPIN1
exons, exon/intron boundaries, and 3 untranslated region were
sequenced in 158 patients with idiopathic severe insulin resis-
tance (including 23 lipodystrophic patients) and 48 control
subjects.
RESULTS—We found no association between LPIN1 single
nucleotide polymorphisms and fasting insulin but report a nom-
inal association between rs13412852 and BMI (P  0.042) in a
meta-analysis of 8,504 samples from in-house and publicly avail-
able studies. Three rare nonsynonymous variants (A353T, R552K,
and G582R) were detected in severely insulin-resistant patients.
However, these did not cosegregate with disease in affected
families, and Lipin1 protein expression and phosphorylation in
patients with variants were indistinguishable from those in
control subjects.
CONCLUSIONS—Our data do not support a major effect of
common LPIN1 variation on metabolic traits and suggest that
mutations in LPIN1 are not a common cause of lipodystrophy in
humans. The nominal associations with BMI and other metabolic
traits in U.K. cohorts require replication in larger cohorts.
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ipin 1, a multifunctional protein highly expressed
in mouse and human adipose tissue, has been
shown to inﬂuence adipose tissue development
and function. Null mutations in the murine lipin 1
gene (Lpin1) result in impaired adipocyte differentiation
leading to a severe reduction in adipose tissue mass,
insulin resistance, and progressive peripheral neuropathy
in the ﬂd and ﬂd
2J mouse models (1). In contrast, trans-
genic mice with adipose tissue–speciﬁc overexpression of
Lpin1 exhibit diet-induced obesity and enhanced insulin
sensitivity compared with those seen in wild-type litter-
mates (2). In humans, LPIN1 expression in adipose tissue
appears to be inversely correlated with measures of adi-
posity such as BMI and positively correlated with insulin
sensitivity (3–6).
The mechanism through which lipin 1 inﬂuences adipos-
ity and insulin sensitivity in mice and humans is not
entirely known. However, recent data indicate that lipin 1
is a magnesium-dependent phospatidate phosphatase re-
sponsible for catalyzing the penultimate step in triacyl-
glyceride synthesis, explaining why Lpin1-deﬁcient ﬂd
mice cannot accumulate fat in mature adipocytes (7).
Lipin 1 is also thought to regulate transcription of genes
involved in adipocyte differentiation (PPAR and
C/EBP), fat synthesis and storage (DGAT, ACC-1,
PEPCK, FAS, and SCD1), and fatty acid oxidation
(CPT-1, AOX, and PPAR) (2,6–10).
There has only been one study sequencing LPIN1 in
lipodystrophic patients (n  15), with no pathogenic
mutation reported (11). Furthermore, although a number
of studies have evaluated the role of common variation in
LPIN1 and metabolic quantitative phenotypes (12–14), the
results have been inconsistent across studies and some-
times within the same study. For example, rs2716610 and
a SNP in high linkage disequilibrium, rs2716609, were
associated with BMI in a Finnish obesity case-control
study and in the Quebec Family Study (12,14) but not in a
German population-based cohort (the the MONItoring of
trends and determinants in CArdiovascular disease
[MONICA] study) (13). Moreover, LPIN1 haplotypes were
strongly associated with traits underlying the metabolic
syndrome in the MONICA study, but these haplotypes
often had the opposite effect on the same traits in a
replication cohort (13). This inconsistency suggests that
further studies are needed to clarify the role of LPIN1
variation on human metabolic traits. In this study, we have
taken complementary approaches to study the role of
LPIN1 variation in human metabolic traits in U.K. popu-
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DIABETES, VOL. 57, SEPTEMBER 2008 2527lations: 1) we genotyped 22 SNPs that tag common LPIN1
variation (minor allele frequency 0.01) in two white U.K.
population-based cohorts (n  4,610) and tested for
association with fasting serum insulin levels, BMI, and a
number of additional metabolic traits with previously
reported association with LPIN1, and 2) we sequenced
LPIN1 in a cohort of patients with syndromes of severe
insulin resistance (n  135) and lipodystrophy (n  23) to
identify potentially pathogenic mutations.
RESEARCH DESIGN AND METHODS
Deﬁnition of cohorts
ELY cohort. The MRC Ely Study is a population-based cohort study of the
etiology and pathogenesis of type 2 diabetes and related metabolic disorders
in the U.K. (15). The subject population is comprised of white men and women
aged 35–79 years without diagnosed diabetes. Measurements of anthropomet-
ric and metabolic data analyzed in this study have previously been described
(16). Informed consent was obtained from all participants, and ethical
approval for the study was granted by the Cambridge Local Research Ethics
Committee.
Hertfordshire cohort. The study population comprising the Hertfordshire
Cohort was recruited from the Hertfordshire population born between 1931
and 1939. The cohort details and measurements of metabolic traits analyzed in
this study have previously been described (17).
European Prospective Investigation into Cancer and Nutrition–Obe-
sity study. The European Prospective Investigation into Cancer and Nutrition
(EPIC)-Obesity study is nested within the EPIC-Norfolk study, a population-
based cohort study of 25,663 white European men and women aged 39–79 and
recruited in Norfolk, U.K., between 1993 and 1997 (18). Height and weight
were measured using standard anthropometric techniques (18). All samples
were genotyped using the Affymetrix GeneChip Human Mapping 500K Array
Set, which contained genotype information for ﬁve of our LPIN1 tagSNPs,
each of which had a call rate 90%. In total, 2,415 individuals with height and
weight measures and quality-controlled genotype data were available for
analyses.
Human genome diversity cell line panel and Centre d’Etude du Poly-
morphisme Humain. The Human Genomse Diversity Cell Line Panel (HGDP)
Centre d’Etude du Polymorphisme Humain (CEPH) is a resource of 1,064 DNA
samples from individuals distributed around the world and has previously
been described (19). The 48 unrelated individuals from CEPH families
supplied by Coriell Cell Repositories (20) are control individuals of north and
west European origin.
Severe insulin resistance cohort. All patients had severe insulin resistance,
deﬁned as fasting insulin above 150 pmol/l or peak insulin on oral glucose
tolerance testing 1,500 pmol/l in nondiabetic patients. Complete insulin
deﬁciency was deﬁned as an insulin requirement above 3 units  kg
1  day
1.
Most patients had a BMI 30 kg/m
2, and at least 58 patients had BMI 30
kg/m
2. Those with partial -cell decompensation and clinical features includ-
ing acanthosis nigricans and those with BMI 30 kg/m
2 were included at the
investigators’ discretion. All patients gave informed consent with approval of
the local research ethics committee in Cambridge, U.K.
Selection of single nucleotide polymorphisms to common tag LPIN1
variation. Tag single nucleotide polymorphisms (SNPs) were selected to
cover variation with minor allele frequency (MAF) 1% present in LPIN1 and
its ﬂanking 4-kb regions (chromosome 2, coordinates 11800212–11889941
[NCBI B36 assembly]). The International HapMap (release 20, phase II)
reports 61 SNPs for CEPH Utah (CEU) samples in this chromosomal region,
while we identiﬁed ﬁve novel SNPs during resequencing of 48 CEPH individ-
uals (supplementary Table 1, available in an online appendix at http://
dx.doi.org/10.2337/db08-0422). Twenty-ﬁve tag SNPs were selected to cover all
66 novel and known HapMap polymorphisms with a pairwise r
2  0.8 using
Tagger (21) as a stand-alone program in Haploview (22) (supplementary Fig.
1). Twenty-two of these tag SNPs passed assay design and prescreening
(supplementary Table 2). The three failed SNPs tagged only ﬁve intronic SNPs.
We calculated that we have 80% power to detect a per-allele effect on BMI
of 1.33 kg/m2 with MAF 0.01 and 0.27 kg/m2 with MAF 0.5. For logged
fasting insulin data, this range is 1.04 to 1.22.
Genotyping. Genotyping was performed by the genotyping facility within the
Genetics of Complex Traits in Humans team at the Wellcome Trust Sanger
Institute. LPIN1 mutations A353T, R552K, and G582R were genotyped on the
CEPH human diversity panel as stand-alone assays using the Sequenom
MassArray hME platform ((Sequenom, San Diego, CA) according to the
manufacturer’s instructions. Twenty-two LPIN1 tagging SNPs (supplementary
Table 2) were genotyped using the Sequenom MassArray iPlex platform
according to the manufacturer’s instructions. Details regarding primers,
probes, and conditions are available on request. All SNPs, except for
rs17603755, were successfully genotyped in 85% of samples (call rates for
TABLE 1
Mean fasting insulin levels and mean BMI of study participants by LPIN1 tagSNP genotype in the MRC Ely cohort and the
Hertfordshire cohort studies
SNP
Ely
Insulin (pmol/l) BMI (kg/m
2)
012 P 012 P
rs893346 49.18  1.02 47.65  1.05 57.57  1.08 0.609 27.23  0.13 27.5  0.39 26.3  1.7 0.303
rs4669778 49.99  1.03 48.88  1.02 47.23  1.03 0.216 27.42  0.24 27.41  0.16 27.11  0.27 0.109
rs893345 48.17  1.03 48.69  1.02 49.76  1.03 0.424 27.27  0.28 27.75  0.32 25.87  1.57 0.967
rs7595221 47.75  1.03 50.08  1.02 48.59  1.04 0.55 27.11  0.22 26.99  0.24 26.09  0.92 0.815
Novel1 48.46  1.02 49.79  1.03 49.67  1.08 0.409 27.15  0.15 27.49  0.21 27.01  0.64 0.393
rs16857866 49.1  1.01 53.35  1.08 47.7  0 0.398 27.23  0.12 28.02  0.64 29.65  0 0.215
rs13412852 50.18  1.02 48.63  1.02 45.1  1.05 0.042 27.42  0.18 27.36  0.18 26.44  0.35 0.054
rs2278513 47.41  1.03 49.45  1.02 48.82  1.04 0.37 27.06  0.22 27.28  0.16 27.45  0.26 0.467
rs3795974 48.59  1.02 49.57  1.02 49.93  1.04 0.441 27.21  0.19 27.76  0.96 27.86  3.19 0.844
rs33997857 48.95  1.01 46.11  1.1 56.18  1.9 0.627 27.24  0.12 27.7  0.67 28.76  0.57 0.401
rs17603350 48.99  1.02 47.89  1.05 99.5  1.37 0.986 27.34  0.13 26.3  0.36 27.52  1.28 0.031
rs17603420 50.63  1.03 47.75  1.02 49.14  1.03 0.271 27.33  0.2 27.39  0.18 26.9  0.25 0.269
rs6729430 48.95  1.02 45.77  1.1 49.99  1.47 0.61 27.24  0.12 27.39  0.34 29.79  1.28 0.508
rs2577264 48.61  1.02 48.91  1.02 50.6  1.04 0.368 27.19  0.2 27.37  0.18 27.21  0.3 0.733
rs2577262 49.25  1.02 48.96  1.02 48.72  1.05 0.639 27.24  0.17 27.61  0.28 27.99  0.86 0.857
rs2577261 49.52  1.02 46.67  1.03 48.09  1.12 0.15 27.18  0.12 27.38  0.18 27.23  0.3 0.256
rs4669781 48.91  1.02 49.56  1.04 43.59  1.21 0.844 27.22  0.12 27.19  0.18 27.25  0.29 0.780
rs2716609 48.99  1.02 48.25  1.05 44.85  1.2 0.61 27.13  0.15 27.34  0.17 26.82  0.24 0.073
Novel2 48.11  1.02 50.44  1.04 52.4  1.17 0.117 27.25  0.12 27.25  1.26 0  0 0.987
rs1050800 49.01  1.01 47.15  1.19 0  0 0.728 27.21  0.14 27.34  0.23 26.55  0.62 0.993
rs2577256 48.81  1.02 49.32  1.03 49.09  1.09 0.862 27.02  0.24 27.41  0.19 26.94  0.38 0.208
Data are means  SE. The P values indicate the results of a regression analysis assuming an additive model of gene action (nominally
signiﬁcant values, P  0.05, are highlighted in bold). For fasting insulin, the analysis was performed on log-transformed data, and the table
shows geometric means and SEs. 0, homozygous for the major allele (refer to Supplementary table 2); 1, heterozygous; and 2, homozygous
for the minor allele.
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Hardy-Weinberg Equilibrium (P  0.01). The average call rate across Ely and
Hertfordshire samples pooled together was 92.1%.
Statistical analysis. Deviation of LPIN1 tagSNP genotype from Hardy-
Weinberg equilibrium was assessed using a goodness-of-ﬁt 
2 test. Linear
regression analysis was used to assess the association between individual
SNPs and BMI, log-transformed fasting plasma insulin, and log-transformed
additional metabolic traits (systolic and diastolic blood pressure, HDL and
LDL cholesterol, plasma triglycerides, waist circumference, and A1C levels) in
Ely and Hertfordshire cohorts using Stata (version 9; Stata, College Station,
TX). All analyses were adjusted for age and sex and, in the case of the joint
analysis, included an indicator term for study. Logistic regression in Stata was
used to test for association between LPIN1 SNPs and risk of hypertension and
diabetes. 
2 analysis was performed to test for signiﬁcant differences (P 
0.01) in call rate between cases and controls. The joint Ely and Hertfordshire
cohort analysis of additional traits underlying metabolic syndrome was
comprised of 189 tests, so the P value threshold adjusted for multiple testing
using the Bonferroni correction is 0.0003. Fixed-effects meta-analysis using
the inverse variance method was performed by using the “metan” command in
Stata (23). Heterogeneity among studies was assessed using the Q statistic.
IMPUTE software (http://www.stats.ox.ac.uk/	marchini/software/gwas/
impute.html) was used to impute genotypes for rs17603420 in the EPIC
cohort. Plink (http://pngu.mgh.harvard.edu/	purcell/plink/) was used to
perform hapotype analysis (24), and Ely and Hertfordshire cohorts were
meta-analyzedusingMETAL(http://www.sph.umich.edu/csg/abecasis/metal/
index.html).
PCR and sequencing. Genomic DNA from patients was randomly preampli-
ﬁed in a GenomiPhi reaction (GE Healthcare UK, Chalfont St. Giles, U.K.)
before ampliﬁcation with gene-speciﬁc primers (designed using Primer3
software [http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi]) covering
all coding exons, splice junctions, and 3 untranslated region (sequences and
cycling conditions available on request). PCR was performed using standard
conditions, and products were puriﬁed using exonuclease I and shrimp
alkaline phosphatase (USB, Cleveland, OH). Bidirectional sequencing was
performed using the Big Dye Terminator 3.1 kit (Applied Biosystems, Foster
City, CA). Sequencing reactions were run on ABI3730 capillary machines
(Applied Biosystems) and analyzed using Mutation Surveyor (version 2.20;
SoftGenetics, State College, PA). All nonsynonymous variants with MAF
0.01 were conﬁrmed in a second PCR and sequencing reaction using patient
genomic DNA. DNA from family members used for cosegregation analysis was
genomic. Only one amplicon within the 3 untranslated region failed sequenc-
ing, and all others passed on 85% of samples (with an average pass rate of
95%). PANTHER was used to predict the functional impact of nonsynonymous
mutations (http://www.pantherdb.org/tools/csnpScoreForm.jsp). Sequencing
of preampliﬁed CEPH samples was done in the same way.
Western blotting. Patient ﬁbroblast cells were maintained in Dulbecco’s
modiﬁed Eagle’s supplemented with 10% fetal bovine serum and 2 mmol/l
L-glutamine in a humidiﬁed 37°C incubator with 5% CO2. All cells were
routinely assessed for and protected against Macroplasma pulmonis infection
using VenorGeM Mycoplasma detection kit (VGM-025; Minerva Biolabs,
CamBio) and BM-cyclin (799050; Roche) respectively. Fibroblasts were col-
lected by trypsin EDTA release, washed with PBS, and then lysed in a 50
mmol/l HEPES pH7.4 buffer containing 150 mmol/l NaCl; 1% Triton X-100; 100

mol/l 4-(2-aminoethyl)-benzenesulfonyl ﬂuoride, hydrochloride; protease in-
hibitor cocktail 1; phosphatase inhibitor cocktail II; 1 
g/ml Dnase; and 4
mmol/l MgCl2 chilled to 4°C. Each sample was homogensized by passing
through a 25-gauge needle 10 times. Insoluble debris was removed by a
16,000g centrifugation step at 4°C. Sample protein concentration was mea-
sured by a comparative Bradford protein assay. Samples were then suspended
in 1 SDS sample buffer and boiled at 95°C for 5 min, loaded onto 7%
SDS-PAGE, transferred onto nitrocellulose, and blocked in PBS with 1%
TX-100 and 5% milk. These were then probed with protein-speciﬁc primary
antibodies: lipin 1, lipin 2, anti-Mab414 (MMS-120P; Covance), anti-laminB
(sc-6217; Santa-Cruz;). Lipin 1 and 2 polyclonal antibody production will be
described elsewhere (N.G. and S.S., unpublished observations). This was
followed by species-speciﬁc secondary antibodies coupled to horseradish
peroxidase: anti-rabbit IgG (211-032-171; Jackson ImmunoResearch), anti-goat
IgG (NB 710-H; Novus Biologicals), anti-mouse IgG (H & L) highly cross-
adsorbed (A11029; Molecular Probes). Proteins were then detected using
standard electrochemiluminescence techniques (Amersham ECL reagents).
Indirect immunoﬂuorescence by confocal microscopy. Fibroblasts were
ﬁxed with 3% formaldehyde, permiablized with 0.1% Triton X-100, and blocked
with 1 mg/ml BSA in PBS. Each coverslip was labeled with primary mouse
Mab414 (nuclear pore marker) and secondary anti-mouse conjugated to
ﬂuorescein isothiocyanate (green), primary rabbit endoplasmic reticulum
calcium-binding protein (Calreticulin, no. 208910; Calbiochem), and second-
ary anti-rabbit conjugated to Alexa ﬂuor 594 (red) (A11037; Molecular
Probes). DNA was stained with DAPI (blue). Each slide was mounted onto
TABLE 1
Continued
Hertfordshire
Insulin (pmol/l) BMI (kg/m
2)
012 P 012 P
70.6  1.01 72.33  1.04 78.17  1.2 0.486 27.36  0.09 27.43  0.24 26.14  1.08 0.993
71.28  1.02 72.11  1.02 69.06  1.03 0.409 27.41  0.16 27.37  0.12 27.33  0.16 0.719
71.15  1.03 71.73  1.02 69.14  1.03 0.406 27.21  0.17 27.38  0.12 27.49  0.17 0.234
70.01  1.02 71.45  1.02 70.3  1.03 0.708 27.34  0.14 27.44  0.12 27.23  0.19 0.734
71.71  1.02 70.63  1.02 71.25  1.06 0.575 27.34  0.1 27.52  0.16 27.72  0.45 0.172
70.96  1.01 72.11  1.06 0  0 0.734 27.36  0.09 27.8  0.4 0  0 0.306
70.57  1.02 71.63  1.02 69.18  1.04 0.89 27.47  0.13 27.36  0.12 27.15  0.2 0.249
69.47  1.02 71.46  1.02 72.34  1.03 0.234 27.45  0.14 27.32  0.12 27.42  0.2 0.753
71.04  1.02 70.16  1.02 72.91  1.04 0.602 27.31  0.13 27.41  0.13 27.42  0.22 0.633
70.82  1.01 78.33  1.07 73.83  0 0.166 27.36  0.08 27.91  0.44 25.2  0 0.259
71.27  1.01 67.78  1.05 60.16  2.08 0.282 27.4  0.09 27.15  0.36 30.9  4.96 0.725
70.43  1.02 71.41  1.02 70.26  1.03 0.971 27.58  0.16 27.42  0.12 26.92  0.17 0.01
70.98  1.01 71.68  1.08 0  0 0.849 27.34  0.08 28.37  0.53 0  0 0.053
71.27  1.02 69.8  1.02 73.51  1.04 0.644 27.28  0.13 27.39  0.12 27.48  0.23 0.462
70.76  1.02 71.58  1.02 69.77  1.04 0.95 27.47  0.12 27.37  0.13 26.98  0.25 0.148
71.08  1.02 71.39  1.03 73.5  1.08 0.719 27.23  0.09 27.67  0.22 29.06  0.72 0.006
71.03  1.01 69.44  1.03 66.11  1.11 0.426 27.41  0.09 27.02  0.24 26.81  2.07 0.126
71.19  1.01 69.03  1.04 78.39  1.22 0.597 27.35  0.1 27.42  0.17 27.82  0.66 0.465
71.65  1.02 68.38  1.03 76.59  1.08 0.34 27.38  0.08 25.71  0.72 0  0 0.103
71.02  1.01 69.3  1.15 0  0 0.848 27.4  0.1 27.34  0.16 27.14  0.55 0.585
70.48  1.02 71.77  1.02 74.09  1.07 0.386 27.19  0.16 27.42  0.12 27.47  0.18 0.219
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 or 100 Plan Apochromat
objective lens (numerical aperture 1.4) on a Ziess Axiovert 200M inverted
microscope with an LSM 510 confocal laser-scanning attachment.
RESULTS
Association studies of LPIN1 tag SNPs. Twenty-one
LPIN1 tag SNPs were successfully genotyped in two white
U.K. population–based cohorts: the MRC Ely study (n 
1,709) and the Hertfordshire cohort study (n  2,901). In
the MRC Ely cohort, the minor allele of rs13412852 is
nominally associated with lower fasting insulin levels (P 
0.041) and the minor allele of rs17603350 is nominally
associated with higher BMI (P  0.031), but these associ-
ations are not replicated in the Hertfordshire cohort
(Table 1). Conversely, in the Hertfordshire cohort, and not
in the MRC Ely cohort, rs17603420 and rs2577261 are
nominally associated with BMI (P  0.01 and P  0.006,
respectively) (Table 1). In a joint analysis of the pooled Ely
and Hertfordshire cohorts (supplementary Table 3), no
SNPs were associated with fasting insulin levels, but
rs13412852, rs17603420 and rs2577261 were nominally
associated with BMI (P  0.05). Two of these SNPs,
rs13412852 and rs2577261, overlapped with SNPs on the
Affymetrix 500k and Illumina 300k SNP chips, and
rs17603420 could be imputed. Consequently, we were able
to increase the power of our study to detect modest effects
of these SNPs on BMI by performing meta-analyses with
in-house data (EPIC-Obesity study; n  2,415) and, in the
case of rs13412852 and rs2577261, with data deposited by
the Wellcome Trust Case Control Consortium and the
Wellcome Trust Sanger Institute and published online
from the British 1958 DNA collection (n  1,479) (http://
www.b58cgene.sgul.ac.uk/, accessed January 2008). SNPs
rs2577261 and rs17603420 were not associated with BMI in
the meta-analysis (P  0.114 and 0.071, respectively).
However, the association between rs13412852 and BMI
remained marginally statistically signiﬁcant (P  0.042) in
the meta-analysis (Fig. 1).
In analyses of pooled Ely and Hertfordshire cohorts, a
number of nominal associations (P  0.05) were detected
between LPIN1 tag SNPs and traits previously reported to be
associated with LPIN1 variation (13). These data are pre-
sented in supplementary Tables 4 and 5. For SNPs overlap-
ping with the Affymetrix 500k SNP chip, meta-analyses were
performed on continuous traits with publicly available data
from the Broad Institute (http://www.broad.mit.edu/diabetes/
scandinavs/metatraits.html) (supplementary Table 4). For
rs2577256, meta-analysis was performed with publicly avail-
able Wellcome Trust Case Control Consortium data to test
for association with diabetes and hypertension (supplemen-
tary Table 5).
Mutation screening in the severe insulin resistance
cohort. A total of 44 variants were detected in insulin-
resistant or lipodystrophic patients (supplementary Table
1), eight of which were present in the coding sequence
(Fig. 2A). Coding sequence variants that did not alter the
amino acid sequence and/or that were also present in
control subjects were considered unlikely to be patho-
genic (shown below the schematic in Fig. 2A). This left
three rare nonsynonymous variants detected to be het-
erozygous (shown above the schematic) that did not fall
within any known functional domains within LPIN1.
A353T was detected in a female patient with a Pakistani
father and British white mother. She presented with
clinical features of severe insulin resistance at 8 years old,
which worsened with weight gain in the second decade,
before improving dramatically with weight loss in adult
life. She had no evidence of lipodystrophy. A353T was
predicted to have no functional impact on the lipin 1
protein by PANTHER. DNA from the patient’s mother,
maternal aunts, and maternal grandparents was sequenced
and demonstrated that the A353T variant did not segregate
with the hallmarks of insulin resistance in the family (Fig.
3A). A353T was also genotyped in 1,064 participants of the
HGDP-CEPH Human Genome Diversity Cell Line Panel
(referred to below as the diversity panel) but was not
detected.
R552K was detected in two unrelated white European
female subjects but not in 1,064 control subjects from the
diversity panel. The ﬁrst proband presented with severe
insulin resistance and femorogluteal lipodystrophy at 15
years old. The lipodystrophy progressed to become gener-
alized in conjunction with the appearance of aggressive
hemolytic anemia and autoimmune liver disease. Liver
failure led to her death at 24 years old. The other proband
was diagnosed with insulin-resistant diabetes at 32 years
old and subsequently required in excess of 4 units/day
exogenous insulin to maintain satisfactory glycemic con-
trol. She had no clinical evidence of lipodystrophy, and her
BMI was sustained above 30 kg/m
2. R552 is within a highly
conserved tract (Fig. 2B), and mutation to lysine is pre-
dicted by PANTHER to have deleterious effects on lipin 1
function. Family DNA was not available for cosegregation
analysis for either patient.
G582R was identiﬁed in a white European male with a
complex syndrome. This included severe insulin resis-
tance and severe early-onset sensorimotor neuropathy
that conﬁned him to a wheelchair, a combination reminis-
cent of lipodystrophy/insulin resistance and neuropathy in
the ﬂd mouse. This patient also underwent allogeneic bone
marrow transplantation in childhood for acute lympho-
blastic leukemia and had a cerebral cavernous hemangi-
oma. All genomic analyses were undertaken on DNA
extracted from cultured skin ﬁbroblasts. G582 is a well-
conserved residue within the protein (Fig. 2B), and muta-
tion to arginine is predicted by PANTHER to have
deleterious effects on lipin 1 function. Cosegregation anal-
ysis was performed using DNA from ﬁrst-degree relatives
of the patient (Fig. 3B). The father also carried the variant,
but although he was diagnosed with diabetes at age 69
years, he had no peripheral neuropathy or clinical or
biochemical evidence of insulin resistance/lipodystrophy.
 
 Effect size
 -.7  0  .7
 Study
 Effect size
 (95% CI)  % Weight
 Ely  -0.35 (-0.70, 0.01) 15.2 
 Hertfordshire  -0.14 (-0.38, 0.10) 32.6 
 EPIC  -0.11 (-0.33, 0.12) 37.8 
 1958  -0.02 (-0.38, 0.34) 14.5 
 Overall  -0.14 (-0.28, -0.01) 00.0 
FIG. 1. Association between rs13412852 and BMI in individual studies
and combined effect size (overall), P  0.045. 1958, 1958 British Birth
cohort; EPIC, EPIC Obesity cohort; Ely, MRC Ely study; and Hertford-
shire, Hertfordshire cohort study.
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Diversity Panel and detected in a Bedouin control subject
from Nedev, Israel.
In summary, we identiﬁed three rare LPIN1 missense
variants in a cohort of insulin-resistant patients. G582R
and R552K are predicted to be deleterious by PANTHER,
and the proband carrying the G582R variant had a syn-
drome reminiscent of the ﬂd mouse. Thus, despite the
failure of this variant to cosegregate with disease in the
kindred, and despite the absence of available family mem-
bers from the R552K kindred, we elected to investigate the
possibility of impaired lipin 1 function in primary skin
ﬁbroblasts from the probands. As A353T was predicted to
be benign, it did not segregate with disease in the family,
and as no ﬁbroblasts were available, this variant was not
investigated further.
Assessing the functional impact of LPIN1 mutations.
To investigate the impact of R552K and G582R mutations
on lipin 1 protein levels and phosphorylation status, total
cell extracts from patient ﬁbroblasts were probed with
lipin 1, lipin 2, a nuclear pore marker (Mab414), and lamin
B-speciﬁc primary antibodies to detect protein levels
(supplementary Fig. 2A). The resulting Western blot,
shown in supplementary Fig. 2A, shows similar intensities
of all four proteins in patient ﬁbroblasts compared with
those in control cells. Immunocytochemistry was em-
ployed to detect changes in nuclear membrane morphol-
ogy by staining a nuclear pore marker (supplementary Fig.
2B). There was no discernable difference in morphology
between patient and control ﬁbroblasts.
DISCUSSION
In this study, we performed a comprehensive analysis of
LPIN1 variants and their effects on metabolic quantitative
traits and syndromes of insulin resistance (including lipo-
dystrophy). Analysis of LPIN1 common variation (MAF
0.01) in two U.K. population-based cohorts (n  4,610)
revealed nominal signiﬁcant associations with BMI, and
rs13412582 remained marginally associated with BMI (P 
0.042) in a meta-analysis of U.K. population-based samples
from in-house and publicly available genome-wide studies
(n  8,504). We also detected nominal associations be-
tween our tag SNPs and metabolic traits previously re-
ported to be associated with LPIN1 variation (13).
Sequencing of 23 patients with lipodystrophy and 135
patients with syndromes of insulin resistance revealed that
mutations in LPIN1 are not a common cause of these
diseases in humans.
To our knowledge, neither rs13412582 nor any highly
correlated SNPs have been tested in other association
studies published to date. Further replication in larger
cohorts will be required to conﬁrm the association be-
tween rs13412582 and BMI.
Seven of our 21 tag SNPs were directly genotyped in at
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FIG. 2. A: Schematic of the lipin 1 protein showing exons in alternating black and white and known domains among lipin family proteins in gray.
Arrows indicate the location of coding SNPs detected in LPIN1 by sequencing 23 patients with partial lipodystrophy and 135 patients with
other syndromes of severe insulin resistance. Rare (MAF <1%) nonsynonymous mutations (above) were considered potentially pathogenic.
CLIP (amino acids 674–830), COOH-terminal lipin domain, also referred to as the LNS2 (lipin/Ned1/Smp2) domain; HAD, haloacid
dehalogenase domain; NLIP (amino acids 1–114), NH2-terminal lipin domain; and NLS (amino acids 153–158), nuclear localization signal. B:
Multiple sequence alignments (using ClustalW) showing conservation of LPIN1 amino acids A353, R552, and G582. Straight lines indicate
hidden sequence.
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analyses, including our own, found an association between
rs4669781, rs1050800, and rs2577256 and insulin levels and
measures of adiposity. Results for the other four SNPs are
inconsistent between studies. For example, rs2716610 was
associated with BMI in lean Finnish men (12) and with
quantitative measures of adiposity in French-Canadian
families in the Quebec Family Study (14). Here, the highly
correlated SNP rs2716609 (r
2  1.0 in HapMap trios) was
associated with skinfolds and waist circumference, and
BMI showed the same trend. Given our sample size of
4,130 individuals with full rs2716609 genotype and BMI
data, we had 80% power to detect the effect size ob-
served in the Quebec Family study. Nevertheless, we did
not replicate the association between rs2716609 and BMI
or waist circumference in the Ely and Hertfordshire co-
horts (Table 1). Our results agree with the MONICA study
Augsburg (n  1,416), a German population–based cohort,
which found no association between rs2716610 and BMI in
men or women (13).
Two other SNPs, rs893346 and rs2577262, were associ-
ated with BMI in lean Finnish men (12) but showed no
statistical association with BMI in 1,873 lean men from the
Ely and Hertfordshire cohort studies (P  0.631 and 0.253,
respectively). Similarly, rs2278513 and rs2577262 were
associated with BMI in obese Finnish men but not in obese
men from the U.K. (P  0.780 and 0.676, respectively). Our
data agree with the results of the MONICA study, which
showed no association of rs893346 and two SNPs highly
correlated with rs2577262 in HapMap CEU trios (r
2  1.0
and 0.96 for rs6744682 and rs6708316, respectively) with
BMI in men (13).
The MONICA study reported strong associations be-
tween haplotypes of rs33997857, rs6744682, and rs6708316
with hypertension-, obesity-, or diabetes-related traits (13).
Several of the traits were also statistically associated with
the same haplotypes in a replication study, but the effect
was always in the opposite direction compared with the
original cohort. To attempt replication of the MONICA
study data, we tested haplotypes of rs33997857 and
rs2577262 (highly correlated with rs6744682 [r
2  1.0] and
rs6708316 [r
2  0.96] in HapMap CEU trios) against
metabolic traits in the Ely and Hertfordshire cohorts but
only found nominal associations with hypertension (sup-
plementary Table 6). We did detect a number of nominal
associations between these traits and other SNPs in our
study (supplementary Tables 4 and 5). However, none of
these reached statistical signiﬁcance after adjustment of
the P value threshold for multiple testing using the Bon-
ferroni correction, and all require further replication.
There are several possible reasons why we could not
replicate previously reported associations between LPIN1
variants and metabolic quantitative traits. Firstly, we may
have reported false-negative results. However, where ef-
fect sizes were reported in previously published studies,
we were able to calculate that our study had 80% power
to detect them. Secondly, previous studies might have
reported false-positive results. In particular, as a conse-
quence of multiple testing, detection of false-positive
associations becomes more likely when analyses are per-
formed in subsets of samples and on many traits. Further-
more, one has to expect false-positive ﬁndings among
previously reported disease associations given the low
prior probability of detecting a true association with a
complex trait (25). Alternatively, the discrepancy in results
between studies may be due to genetic and/or environmen-
tal differences between the populations genotyped. For
example, the degree of linkage disequilibrium between
LPIN1 tag SNPs and the putative unmeasured true func-
tional variant(s) may vary between the cohorts. Also,
LPIN1 SNPs may interact with other genetic and/or envi-
ronmental risk factors in different studies.
In the ﬂd mouse model, Lpin1-null mutations cause
lipodystrophy, insulin resistance, and peripheral neuropa-
thy (1). However, of the three rare (MAF 0.01) nonsyn-
onymous LPIN1 variants detected within our cohort of
patients with syndromes of severe insulin resistance, none
are likely to be pathogenic in isolation in heterozygous
form; family cosegregation analysis showed that A353T
and G582R did not segregate with disease in a fully
penetrant manner, and G582R was also detected in one
Bedouin control.
Western blotting of patient ﬁbroblasts showed that
G582R and R552K had no discernable impact on lipin 1
protein levels. Proteins orthologous to lipin 1 in yeast are
proposed to be involved in nuclear membrane growth and
morphology (26–28). However, staining of a nuclear pore
+/+ +/-
+/+
+/-
+/- +/-
A
+/- +/+
+/+ +/+ +/-
B
FIG. 3. A: A family pedigree demonstrating that the A353T mutation
does not segregate with disease in a fully penetrant manner. The
patient (indicated by the arrow) has hyperinsulinemia (diagonal
stripes), hirsutism (spots), and acanthosis nigricans (dashes). The
grandfather has diabetes (diamonds). There is no fasting insulin data
for the grandmother or the youngest maternal aunt. , heterozygous
genotype; /, wild-type genotype. B: A family pedigree demonstrating
that the G582R mutation does not segregate with disease in a fully
penetrant manner. The patient (indicated by the arrow) has hyperin-
sulinemia (diagonal stripes), severe peripheral neuropathy (black),
previous bone marrow transplant for acute myeloid leukemia (horizon-
tal stripes), and an intracerebral cavernous hemangioma (vertical
stripes). His father has diabetes (diamonds). , heterozygous geno-
type; /, wild-type genotype.
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variants revealed no abnormalities in membrane morphol-
ogy compared with control ﬁbroblasts.
To date, our study and a previously published work (11),
including 23 and 15 patients with lipodystophy screened,
respectively, have demonstrated that LPIN1 coding muta-
tions are unlikely to be a common cause of human
lipodystrophy. However, we cannot rule out the possibility
that LPIN1 mutations interact with other genetic defects
to cause disease or that they are rarer causes of these
disorders. The methods used to screen for mutations
would not have detected copy number variations affecting
large regions or mutations affecting regulatory regions;
therefore, we cannot exclude these types of LPIN1 varia-
tions as causes of human lipodystrophy and insulin resis-
tance. Furthermore, the in vitro assays used to assess the
functional impact of LPIN1 nonsynonymous variants
might have missed some functional effects, such as phos-
phatidic acid phosphatase activity.
We conclude that LPIN1 coding variants are not a
common cause of lipodystrophy and severe insulin resis-
tance in humans and that polymorphisms in LPIN1 are
unlikely to importantly contribute to insulin sensitivity and
waist circumference in U.K. populations. Nominal associ-
ations between LPIN1 variants and BMI, blood pressure,
cholesterol, triglycerides, A1C, and risk of hypertension
need replicating in larger cohorts.
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